Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.

Early treatment with DMARDs improved short-term disease activity in undifferentiated arthritis, though long-term outcomes ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic medicines in the United States, announced the launch of Tofacitinib Tablets, ...

A combination of two widely available anti-rheumatic drugs offers the first effective and affordable treatment for patients ...

A new review published in Calcified Tissue International highlights major advances in understanding and preventing bone loss ...

Study finds most complaints arise from other meds such as antacids and antibiotics ...

A large case-control study found that adverse drug effects in patients with autoimmune rheumatologic diseases were more ...

Announcing a new publication for Acta Materia Medica journal. Diacerein, an anthraquinone derivative, is emerging as a promising disease-modifying agent in rheumatoid arthritis (RA), because of its ...

Biosimilar DMARDs offer cost-effective and improved outcomes over leflunomide for RA patients unresponsive to methotrexate. The study used a Markov model with data from 25,099 RA patients to simulate ...

Joint pain can be caused by a number of biological, psychological, and social factors. The most common cause of joint pain is different types of arthritis. There is a wide availability of medications ...